ClinicalTrials.gov
public full text
Public Domain
Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i) peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary hypertension after pulmonary endarterectomy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension#208315
- A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease#356568
- Bosentan in Children With Pulmonary Arterial Hypertension#162326
- Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension#1060391
- Bosentan in Children With Pulmonary Arterial Hypertension Extension Study#148621
Record · ID 1372685
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive